Shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) have been assigned a consensus rating of “Hold” from the thirteen research firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $34.50.
RHHBY has been the subject of several analyst reports. Goldman Sachs Group lowered Roche Holdings AG Basel from a “conviction-buy” rating to a “buy” rating in a report on Monday, November 19th. Citigroup restated a “hold” rating on shares of Roche Holdings AG Basel in a report on Monday, November 26th. ValuEngine upgraded Roche Holdings AG Basel from a “sell” rating to a “hold” rating in a report on Thursday, August 30th. Wolfe Research initiated coverage on Roche Holdings AG Basel in a report on Tuesday, October 23rd. They issued a “market perform” rating for the company. Finally, Bank of America lowered Roche Holdings AG Basel from a “buy” rating to a “neutral” rating in a report on Monday, September 10th.
RHHBY traded down $0.17 on Friday, hitting $31.50. The company had a trading volume of 754,490 shares, compared to its average volume of 1,529,647. Roche Holdings AG Basel has a 1-year low of $26.30 and a 1-year high of $32.58. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market cap of $217.82 billion, a P/E ratio of 16.15, a price-to-earnings-growth ratio of 1.93 and a beta of 0.54.
Hedge funds and other institutional investors have recently modified their holdings of the business. Moloney Securities Asset Management LLC increased its position in Roche Holdings AG Basel by 7.8% in the 3rd quarter. Moloney Securities Asset Management LLC now owns 34,977 shares of the company’s stock worth $1,064,000 after buying an additional 2,525 shares during the period. Pillar Pacific Capital Management LLC increased its position in Roche Holdings AG Basel by 3.8% in the 2nd quarter. Pillar Pacific Capital Management LLC now owns 154,118 shares of the company’s stock worth $4,279,000 after buying an additional 5,635 shares during the period. Ferguson Wellman Capital Management Inc. increased its position in Roche Holdings AG Basel by 2.6% in the 3rd quarter. Ferguson Wellman Capital Management Inc. now owns 322,056 shares of the company’s stock worth $9,713,000 after buying an additional 8,284 shares during the period. Todd Asset Management LLC increased its position in Roche Holdings AG Basel by 2.3% in the 2nd quarter. Todd Asset Management LLC now owns 118,900 shares of the company’s stock worth $3,285,000 after buying an additional 2,700 shares during the period. Finally, Cornerstone Investment Partners LLC bought a new position in Roche Holdings AG Basel in the 3rd quarter worth approximately $206,000. 0.32% of the stock is currently owned by institutional investors.
About Roche Holdings AG Basel
Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.
See Also: Catch-Up Contributions
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.